Search - tctmd.com

Displaying 341 - 360 of 408

Sort: Relevancy | Date

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

Leah Lawrence

August 18, 2016

News Daily News

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

L.A. McKeown

August 11, 2016

News Daily News

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

L.A. McKeown

August 04, 2016

News Daily News

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Todd Neale

August 04, 2016

News Daily News

遗传上更高的血脂水平似乎可预防 2 型糖尿病

Todd Neale

August 04, 2016

News Daily News

Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2

Todd Neale

August 04, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

L.A. McKeown

February 03, 2016

Advertisement

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

遗传上更高的血脂水平似乎可预防 2 型糖尿病

Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content